News & Updates
Filter by Specialty:
Does TB influence viral suppression in HIV patients on DTG-based therapy?
Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.
Does TB influence viral suppression in HIV patients on DTG-based therapy?
16 Aug 2022
Survival benefit with postchemoradiation immunotherapy affirmed
Starting immunotherapy after chemotherapy and radiation for unresectable stage III nonsmall cell lung cancer (NSCLC) prolongs overall survival, regardless of patient age, health, and socioeconomic status, according to a large US study.
Survival benefit with postchemoradiation immunotherapy affirmed
15 Aug 2022
Subgroup analyses boost masupirdine potential for AD
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).
Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.